Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
Significance: Sarcopenia, or aging-associated muscle atrophy, increases the risk of falls and fractures and is associated with metabolic disease. Because skeletal muscle is a major contributor to glucose handling after a meal, sarcopenia has significant effects on whole-body glucose metabolism. Despite the high prevalence and potentially devastating consequences of sarcopenia, no effective therapies are available. Here, we show that treatment of mice with an anti-myostatin antibody for just 4 wk increased muscle mass and strength in both young and old mice. In old mice, this increase in muscle mass was accompanied by an improvement in muscle insulin sensitivity. These data provide support for myostatin inhibition as a potential therapeutic strategy for aging-associated sarcopenia and insulin resistance.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro trials demonstrate that myostatin inhibitors increase muscle mass and strength446, suppress irisin, downregulate inflammatory cytokines and improve insulin resistance447.”
From Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies (2018) · cites this paper as [446]
In the citing paper
“Although there are various approved and effective drugs for diabetes, there is currently no recommended pharmacological intervention for SO, not even for diabetics with SO.”
From Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments (2020) · cites this paper as [178]
In the citing paper
“In mice, even short-term treatment (approximately 4-weeks) with an antimyostatin antibody results in increased whole body muscle mass, grip strength, and insulin action (Camporez et al., 2016).”
From Myosteatosis in the Context of Skeletal Muscle Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging (2020) · cites this paper as Camporez et al., 2016
In the citing paper
“Triglycerides and ectopic lipids also decrease with increased sensitivity in both muscle and liver.”
From Myosteatosis in the Context of Skeletal Muscle Function Deficit: An Interdisciplinary Workshop at the National Institute on Aging (2020) · cites this paper as Camporez et al., 2016
Citations
Cites
A SIMPLE METHOD FOR THE ISOLATION AND PURIFICATION OF TOTAL LIPIDES FROM ANIMAL TISSUES
Folch, J., Lees, M., & Stanley, G. H. S. (1957) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64849-5 · Cited by 65,189 · cited 1×
“(36) from animals fasted for 6 h and measured by”
MethodRegulation of skeletal muscle mass in mice by a new TGF-p superfamily member
McPherron, A. C., Lawler, A. M., & Lee, S.-J. (1997) · Nature · doi:10.1038/387083a0 · Cited by 4,013 · cited 3×
“Myostatin is considered a master regulator of skeletal muscle growth; its inactivation leads to impressive muscle hypertrophy (11) and its overexpression induces muscle atrophy (13).”
BackgroundEpidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Mitochondrial dysfunction in the elderly: possible role in insulin resistance
Petersen, K. F., Befroy, D., Dufour, S., Dziura, J., Ariyan, C., Rothman, D. L., DiPietro, L., Cline, G. W., & Shulman, G. I. (2003) · Science · doi:10.1126/science.1082889 · Cited by 2,107 · cited 1×
“Given the high prevalence of sarcopenia, muscle insulin resistance and type 2 diabetes in older people (33, 34), our findings suggest that myostatin inhibition may be a particularly useful therapeutic strategy in older adults with these common and debilitating conditions.”
BackgroundSelf-citationThe healthcare costs of sarcopenia in the United States
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., & Roubenoff, R. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2004.52014.x · Cited by 1,546 · cited 1×
“Int J Biochem Cell Biol 45(10):2333–2347.”
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Kirkman, M. S., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Diabetes Care · doi:10.2337/dc12-1801 · Cited by 1,274
Clop, A., Marcq, F., Takeda, H., Pirottin, D., Tordoir, X., Bibé, B., Bouix, J., Caiment, F., Elsen, J.-M., Eychenne, F., et al. (2006) · Nature Genetics · doi:10.1038/ng1810 · Cited by 1,260
Induction of Cachexia in Mice by Systemically Administered Myostatin
Zimmers, T. A., Davies, M. V., Koniaris, L. G., Haynes, P., Esquela, A. F., Tomkinson, K. N., McPherron, A. C., Wolfman, N. M., & Lee, S.-J. (2002) · Science · doi:10.1126/science.1069525 · Cited by 907 · cited 1×
“Myostatin is considered a master regulator of skeletal muscle growth; its inactivation leads to impressive muscle hypertrophy (11) and its overexpression induces muscle atrophy (13).”
BackgroundMosher, D. S., Quignon, P., Bustamante, C. D., Sutter, N. B., Mellersh, C. S., Parker, H. G., & Ostrander, E. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030079 · Cited by 826
Suppression of body fat accumulation in myostatin-deficient mice
McPherron, A. C., & Lee, S.-J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0213562 · Cited by 505 · cited 1×
“In particular, myostatin knockout mice with marked skeletal muscle hypertrophy displayed increased energy expenditure (16, 17).”
BackgroundInhibition of myostatin in adult mice increases skeletal muscle mass and strength
Whittemore, L.-A., Song, K., Li, X., Aghajanian, J., Davies, M., Girgenrath, S., Hill, J. J., Jalenak, M., Kelley, P., Knight, A., et al. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02953-4 · Cited by 503 · cited 2×
“Myostatin inhibition in postnatal life increases muscle mass (23, 24), Fig.”
BackgroundGuo, T., Jou, W., Chanturiya, T., Portas, J., Gavrilova, O., & McPherron, A. C. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004937 · Cited by 402
Myostatin and the skeletal muscle atrophy and hypertrophy signaling pathways
Rodriguez, J., Vernus, B., Chelh, I., Cassar-Malek, I., Gabillard, J. C., Hadj Sassi, A., Seiliez, I., Picard, B., & Bonnieu, A. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1689-x · Cited by 397 · cited 1×
“These events stimulate phosphorylation of Smad2 and Smad3, which join with Smad4 into a Smad2/3/4 complex that triggers gene transcription (12).”
BackgroundFast/Glycolytic Muscle Fiber Growth Reduces Fat Mass and Improves Metabolic Parameters in Obese Mice
Izumiya, Y., Hopkins, T., Morris, C., Sato, K., Zeng, L., Viereck, J., Hamilton, J. A., Ouchi, N., LeBrasseur, N. K., & Walsh, K. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.11.003 · Cited by 395 · cited 1×
“Indeed, such a phenotype was observed in mice with skeletal musclespecific expression of a constitutively active Akt1 (15).”
BackgroundAvignon, A., Radauceanu, A., & Monnier, L. (1997) · Diabetes Care · doi:10.2337/diacare.20.12.1822 · Cited by 363 · cited 1×
“For older people in particular, declining muscle mass causes morbidity from loss of strength and mobility (4), reduced bone mineral density (5), reduced energy expenditure (6), changes in body composition favoring increased adiposity (7), increased insulin resistance (8), and increased incidence of type 2 diabetes (9).”
BackgroundMyostatin/activin pathway antagonism: molecular basis and therapeutic potential
Han, H. Q., Zhou, X., Mitch, W. E., & Goldberg, A. L. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.05.019 · Cited by 314 · cited 1×
“Interestingly, myostatin expression has been reported to be increased in several human diseases associated with skeletal muscle wasting, such as cancer cachexia, AIDS, and heart failure (14).”
BackgroundOptimal management of sarcopenia
Sumukadas, D. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s11473 · Cited by 303
Sarcopenia—consequences, mechanisms, and potential therapies
Greenlund, L. (2003) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(02)00196-3 · Cited by 294 · cited 2×
“Biochem Biophys Res Commun 300(4):965–971.”
BackgroundInsulin Resistance with Aging: Effects of Diet and Exercise
Ryan, A. S. (2000) · Sports Medicine · doi:10.2165/00007256-200030050-00002 · Cited by 282 · cited 1×
“For older people in particular, declining muscle mass causes morbidity from loss of strength and mobility (4), reduced bone mineral density (5), reduced energy expenditure (6), changes in body composition favoring increased adiposity (7), increased insulin resistance (8), and increased incidence of type 2 diabetes (9).”
BackgroundBevier, W. C., Wiswell, R. A., Pyka, G., Kozak, K. C., Newhall, K. M., & Marcus, R. (1989) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650040318 · Cited by 280 · cited 1×
“For older people in particular, declining muscle mass causes morbidity from loss of strength and mobility (4), reduced bone mineral density (5), reduced energy expenditure (6), changes in body composition favoring increased adiposity (7), increased insulin resistance (8), and increased incidence of type 2 diabetes (9).”
BackgroundHaidet, A. M., Rizo, L., Handy, C., Umapathi, P., Eagle, A., Shilling, C., Boue, D., Martin, P. T., Sahenk, Z., Mendell, J. R., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709144105 · Cited by 267 · cited 1×
“Further, long-term myostatin inhibition using a monoclonal antibody against myostatin (24) or a single postnatal intramuscular injection of adenoassociated virus encoding follistatin or other myostatin inhibitors (26) resulted in improvements in muscle strength.”
BackgroundCellular Mechanisms by Which FGF21 Improves Insulin Sensitivity in Male Mice
Camporez, J. P. G., Jornayvaz, F. R., Petersen, M. C., Pesta, D., Guigni, B. A., Serr, J., Zhang, D., Kahn, M., Samuel, V. T., Jurczak, M. J., et al. (2013) · Endocrinology · doi:10.1210/en.2013-1191 · Cited by 228
Self-citationCamporez, J. P. G., Jornayvaz, F. R., Lee, H.-Y., Kanda, S., Guigni, B. A., Kahn, M., Samuel, V. T., Carvalho, C. R. O., Petersen, K. F., Jurczak, M. J., et al. (2013) · Endocrinology · doi:10.1210/en.2012-1989 · Cited by 192 · cited 1×
“clamps were performed as described (37).”
Self-citationThe Epidemiology of Sarcopenia
Janssen, I. (2011) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2011.03.004 · Cited by 191
Is there evidence for an age-related reduction in metabolic rate?
Piers, L. S., Soares, M. J., McCormack, L. M., & O’Dea, K. (1998) · Journal of Applied Physiology · doi:10.1152/jappl.1998.85.6.2196 · Cited by 189 · cited 3×
“For older people in particular, declining muscle mass causes morbidity from loss of strength and mobility (4), reduced bone mineral density (5), reduced energy expenditure (6), changes in body composition favoring increased adiposity (7), increased insulin resistance (8), and increased incidence of type 2 diabetes (9).”
BackgroundNakatani, M., Takehara, Y., Sugino, H., Matsumoto, M., Hashimoto, O., Hasegawa, Y., Murakami, T., Uezumi, A., Takeda, S., Noji, S., et al. (2008) · The FASEB Journal · doi:10.1096/fj.07-8673com · Cited by 187 · cited 1×
“showed that mdx Duchenne muscular dystrophy mice overexpressing the endogenous myostatin inhibitor follistatin displayed increased muscle strength (25).”
BackgroundTransgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistance
Zhao, B., Wall, R. J., & Yang, J. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.09.044 · Cited by 186
Longitudinal changes in adult fat-free mass: influence of body weight
Forbes, G. B. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/70.6.1025 · Cited by 183 · cited 1×
“For older people in particular, declining muscle mass causes morbidity from loss of strength and mobility (4), reduced bone mineral density (5), reduced energy expenditure (6), changes in body composition favoring increased adiposity (7), increased insulin resistance (8), and increased incidence of type 2 diabetes (9).”
BackgroundLeBrasseur, N. K., Schelhorn, T. M., Bernardo, B. L., Cosgrove, P. G., Loria, P. M., & Brown, T. A. (2009) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glp068 · Cited by 180 · cited 5×
“However, a previous study (27) failed to show increased grip strength in aged mice (24 mo old) after 4 wk of treatment with an anti-myostatin antibody (PF-354), whereas another study (28) showed just increased in situ muscle strength of aged (21 mo old) mice treated with this same antibody for 14 wk.”
BackgroundMethodInfluentialModulating skeletal muscle mass by postnatal, muscle‐specific inactivation of the myostatin gene
Grobet, L., Pirottin, D., Farnir, F., Poncelet, D., Royo, L. J., Brouwers, B., Christians, E., Desmecht, D., Coignoul, F., Kahn, R., et al. (2003) · genesis · doi:10.1002/gene.10188 · Cited by 180 · cited 1×
“Myostatin inhibition in postnatal life increases muscle mass (23, 24), Fig.”
BackgroundDyle, M. C., Ebert, S. M., Cook, D. P., Kunkel, S. D., Fox, D. K., Bongers, K. S., Bullard, S. A., Dierdorff, J. M., & Adams, C. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.556241 · Cited by 138 · cited 1×
“subjected to five consecutive tests to obtain the peak value, as described (35).”
MethodMurphy, K. T., Koopman, R., Naim, T., Léger, B., Trieu, J., Ibebunjo, C., & Lynch, G. S. (2010) · The FASEB Journal · doi:10.1096/fj.10-159608 · Cited by 124 · cited 1×
“However, a previous study (27) failed to show increased grip strength in aged mice (24 mo old) after 4 wk of treatment with an anti-myostatin antibody (PF-354), whereas another study (28) showed just increased in situ muscle strength of aged (21 mo old) mice treated with this same antibody for 14 wk.”
BackgroundBernardo, B. L., Wachtmann, T. S., Cosgrove, P. G., Kuhn, M., Opsahl, A. C., Judkins, K. M., Freeman, T. B., Hadcock, J. R., & LeBrasseur, N. K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011307 · Cited by 69 · cited 1×
“Indeed, myostatin knockout mice display increased energy expenditure (29) and protection against lipid-induced insulin resistance, glucose intolerance, and HFD-induced obesity (16, 30–32).”
BackgroundMyostatin Inhibition Prevents Diabetes and Hyperphagia in a Mouse Model of Lipodystrophy
Guo, T., Bond, N. D., Jou, W., Gavrilova, O., Portas, J., & McPherron, A. C. (2012) · Diabetes · doi:10.2337/db11-0915 · Cited by 68
Camporez, J. P. G., Kanda, S., Petersen, M. C., Jornayvaz, F. R., Samuel, V. T., Bhanot, S., Petersen, K. F., Jurczak, M. J., & Shulman, G. I. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054080 · Cited by 58
Self-citationChoi, S. J., Yablonka-Reuveni, Z., Kaiyala, K. J., Ogimoto, K., Schwartz, M. W., & Wisse, B. E. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00656.2010 · Cited by 48 · cited 1×
“In particular, myostatin knockout mice with marked skeletal muscle hypertrophy displayed increased energy expenditure (16, 17).”
Background
Cited by
Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies
Batsis, J. A., & Villareal, D. T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0062-9 · Cited by 1,382
Emerging Targets in Type 2 Diabetes and Diabetic Complications
Demir, S., Nawroth, P. P., Herzig, S., & Ekim Üstünel, B. (2021) · Advanced Science · doi:10.1002/advs.202100275 · Cited by 525
Correa-de-Araujo, R., Addison, O., Miljkovic, I., Goodpaster, B. H., Bergman, B. C., Clark, R. V., Elena, J. W., Esser, K. A., Ferrucci, L., Harris-Love, M. O., et al. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00963 · Cited by 468
“In mice, even short-term treatment (approximately 4-weeks) with an antimyostatin antibody results in increased whole body muscle mass, grip strength, and insulin action (Camporez et al., 2016).”
BackgroundSelf-citationSkeletal Muscle as an Endocrine Organ: The Role of Myokines in Exercise Adaptations
Hoffmann, C., & Weigert, C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a029793 · Cited by 393
“Myostatin deficiency or inhibition of myostatin signaling improves insulin resistance in old and obese mice (Zhao et al. 2005; Wilkes et al. 2009; Camporez et al. 2016).”
Tournadre, A., Vial, G., Capel, F., Soubrier, M., & Boirie, Y. (2019) · Joint Bone Spine · doi:10.1016/j.jbspin.2018.08.001 · Cited by 375
“Among hormonal factors, myostatin is regulated during chronic inflammation and may therefore be involved in inflammatory sarcopenia via its catabolic effects (23).”
Background
Metadata
- Authors
- Camporez, J.-P. G., Petersen, M. C., Abudukadier, A., Moreira, G. V., Jurczak, M. J., Friedman, G., Haqq, C. M., Petersen, K. F., & Shulman, G. I.
- Affiliations
- Yale University (US)
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06520;
- University of Pittsburgh (US)
- Atara Biotherapeutics (United States) (US)
- Howard Hughes Medical Institute (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2016-02-08
- Volume
- 113
- Issue
- 8
- Pages
- 2212-2217
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4776508
- OpenAlex
- W2261112793
- Cited by
- 184
- References
- 38
- Citations by year
- 2026: 11 · 2025: 14 · 2024: 15 · 2023: 20 · 2022: 14 · 2021: 26 · 2020: 27 · 2019: 17 · 2018: 16 · 2017: 17 · 2016: 7
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK-40936, U24 DK-059635, P30 DK-45735, R24 DK-085638, K01 DK-099402)
- HHS | NIH | National Institute on Aging (R01 AG-23686)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
- Health Sciences › Nursing › Nutrition and Dietetics › Muscle metabolism and nutrition
- Keywords
- myostatin, sarcopenia, skeletal muscle atrophy, aging, muscle mass, muscle strength, insulin sensitivity, insulin-stimulated glucose uptake, hyperinsulinemic-euglycemic clamp, myokines, therapeutic target
- MeSH terms
- Aging, Animals, Antibodies, Monoclonal, Disease Models, Animal, Energy Metabolism, Humans, Insulin Resistance, Male, Muscle, Skeletal, Mice, Muscle Strength, Myostatin, Sarcopenia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.